Request a Rep
Request a Rep

For patients with NYHA class II–III obstructive HCM,



Adverse reactions occurring in >5% of patients and more
commonly in patients on CAMZYOS than in those on placebo*

  CAMZYOS (n=123) Placebo (n=128)
Dizziness, % 27 18
Syncope, % 6 2
  • *Adverse reactions are defined as responses that are unintended, occurring at doses typically used for treatment of disease.2

Effects on systolic function1

  • Mean (SD) resting LVEF was 74% (6) at baseline in both treatment groups
  • Mean (SD) absolute change from baseline in LVEF was -4% (8) in the CAMZYOS group and 0% (7) in the placebo group over the 30-week treatment period
  • At week 38, following an 8-week interruption of trial drug, mean LVEF was similar to baseline for both treatment groups
  • 7 (6%) patients in the CAMZYOS group and 2 (2%) patients in the placebo group experienced reversible reductions in LVEF <50% (median 48%: range 35%-49%) while on treatment
  • In 3 of the 7 patients on CAMZYOS and 1 of the 2 patients on placebo, these reductions were asymptomatic
  • In all 7 patients treated with CAMZYOS, LVEF recovered following interruption of CAMZYOS


Syncope (0.8%) was the only adverse drug reaction leading to discontinuation in patients receiving CAMZYOS.

LVEF=left ventricular ejection fraction; SD=standard deviation.


CAMZYOS Demonstrated a Consistent Safety Profile as Seen in the Pivotal Trial3

EXPLORER-LTE primary objective (interim data): safety outcomes

CAMZYOS® adverse events observed in Explorer-LTE clinical trial, chart CAMZYOS® adverse events observed in Explorer-LTE clinical trial, chart
  • Serious TEAEs occurred in 47 patients (20.3%); in 29 of these patients, the TEAE was related to CAMZYOS or adverse CV events3‡
  • Of the 13 patients (6%) who experienced LVEF <50%, 8 resumed treatment, and 5 withdrew from the trial, of which 1 patient re-enrolled later. None experienced a serious TEAE of heart failure3
  • By Week 120, 4 patients had died due to bacterial endocarditis, cardiac arrest, acute myocardial infarction, or intracerebral hemorrhage (n=1 each), all unrelated to treatment.3
  • CV serious TEAEs of clinical interest are defined as serious TEAEs related to major adverse CV events, atrial fibrillation, ventricular arrhythmias, syncope/presyncope, cardiac failure, hypotension, and QTcF prolongation.3

CV=cardiovascular; QTcF=QT interval corrected using Fridericia’s formula; TEAE=treatment-emergent adverse event.

Mean LVEF Remained >50% at All Trial Visits in EXPLORER-LTE3-5

Exploratory objective (interim data): mean change (SD) in LVEF from baseline§ to Week 120

Mean in LVEF from Baseline to Week 120 chart Mean in LVEF from Baseline to Week 120 chart

Swipe left for full chart

In EXPLORER-LTE (n=231), 13 (5.6%) patients experienced reductions in LVEF <50% while taking CAMZYOS. Of those 13 patients, 8 were able to continue treatment after a 4- to 6-week interruption.3

§Baseline is defined as last non-missing measurement before the first dose of CAMZYOS in MAVA-LTE.3

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.


  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
  2. National Institutes of Health. NIA adverse events and serious adverse events guidelines. Accessed April 28, 2022.
  3. Garcia-Pavia P, Oreziak A, Masri A, et al. Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks. Presented at ESC 2023. Oral presentation 835382.
  4. Lakdawala NK, Afshar K, Barriales-Villa R, et al. Changes in standard of care medication during long-term mavacamten treatment for obstructive hypertrophic cardiomyopathy: results from the EXPLORER cohort of MAVA-long term extension. Presented at ESC 2023. Abstract 83579.
  5. Data on file. BMS-REF-MAVA-0063. Princeton, NJ: Bristol-Myers Squibb Company; 2023.